A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement

Trial Profile

A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2018

At a glance

  • Drugs INCB 54828 (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Therapeutic Use
  • Acronyms FIGHT-203
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 20 Feb 2018 Planned End Date changed from 1 Feb 2019 to 1 Dec 2019.
    • 20 Feb 2018 Planned primary completion date changed from 1 Nov 2018 to 1 Oct 2019.
    • 05 Apr 2017 Primary analysis is expected in January 2019 as per trial design presented at the 108th Annual Meeting of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top